First Fixed-Dose Dual-Blocker Established by European Approval

The European Union Executive Committee approved Helsinn Bio-Pharma's Akynzeo on May 27, 2015, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adults. The oral capsule combines netupitant 300mg and palonosetron 0.5mg in a single dose and entered the approval stage after completing a Phase 3 clinical trial. Netupitant blocks substance P and neurokinin-1 (NK1) receptors, while palonosetron inhibits serotonin-3 (5-HT3) receptors, suppressing both acute and delayed reactions. The key product differentiation lies in managing nausea pathways at different times with a single administration.

Phase 3 Trial Demonstrates Improved Delayed Complete Response

The pivotal Phase 3 trial NCT01339260 randomly assigned 1,455 patients receiving anthracycline and cyclophosphamide therapy to either Akynzeo or palonosetron. Under dexamethasone combination, the delayed complete response rate from 25 to 120 hours was 76.9% for Akynzeo and 69.5% for the control group, with a p-value of 0.001. The full 0 to 120-hour period also showed significant differences at 74.3% and 66.6%, respectively. In high emetogenic cisplatin studies, 90.4% of 121 patients experienced no vomiting over five days, outperforming the 80.1% of 136 patients in the palonosetron group.

Approval Scope and Regulatory History

The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on March 26, 2015, and the Executive Committee granted approval on May 27 without a public advisory committee vote. The indication is for the prevention of acute and delayed CINV associated with high emetogenic cisplatin-based chemotherapy and moderate emetogenic chemotherapy. The U.S. FDA had previously approved the same oral combination on October 10, 2014. Therefore, this event is not a signal of development potential but a regulatory achievement that established a commercial asset stage in both the U.S. and Europe.

Competition is with Multi-Agent Preventive Regimens Rather Than Single Products

Standard preventive regimens combine NK1 antagonists, 5-HT3 antagonists, and dexamethasone according to emetic risk, with olanzapine used as an additional option for high-risk patients instead of ondansetron. Direct competitors include Merck & Co. (MRK)'s Emend (aprepitant and fosaprepitant), Heron Therapeutics (HRTX)'s Cinvanti (aprepitant), Aloxi (palonosetron), and generic ondansetron. Akynzeo combines both classes in a single product, streamlining prescription and administration, but France's health authority rated its clinical improvement as ASMR V compared to the standard combination of setrons, aprepitant, and corticosteroids. The convenience advantage does not immediately translate into overwhelming efficacy, which limits pricing and reimbursement negotiations.

Market Potential and Product Lifecycle

Global Industry Analysts forecasts the global CINV drug market to reach USD 3.8 billion in 2024 and USD 5.1 billion in 2030, with an annual growth rate of 5.1%. Akynzeo competes in this market with combination therapy convenience and long-term receptor blockade against generic aprepitant-based regimens. Helsinn has extended the product lifecycle with intravenous fosnetupitant and palonosetron, and an oral suspension for patients with swallowing difficulties, with the European suspension approved on February 12, 2026. The initial capsule approval provides a foundation for expanding the single asset into a formulation platform, offering long-term value.